Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Glenmark Pharmaceuticals Ltd. on Wednesday announced that it has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa ...

Glenmark Pharmaceuticals has launched injection Acetylcysteine in the US after acquiring its abbreviated new drug application (ANDA) from Aspen Pharma USA. According to SBI Securities, the development ...

Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative that will compete directly with Bayer’s MiraLAX.

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the U.S. market, according to the U.S ...